Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Not exactly sure what tremtelectogene empogeditemcel or "trem-cel" is. It sounds like from the study that the patient took the CD33-targeted therapy Mylotarg which is made by Pfizer, so I don't know how much of a role that the Vor Biopharma therapy had in the CR.
Whatever "trem-cel" is, is seems to be genitically engineered, so #1 like Car-T which is also genitically engineered, it is probably much more expensive that MRKR Multi-TAA, and #2 being genitically engineered, don't know what side effects will be in larger studies, like cytokine release syndrome.
Not sure if MRKR will have any CR's in the upcoming data as that will be for the Active arm patients who are the sickest of the sick.
Maybe next year we will get some CR's in the Adjuvant arm patients (we hope) (both patients and investors).